New York, USA – August 7, 2020 – DDA platform, the major division of Creative Bioarray, is an innovative biotechnology branch focuses on developing unique technologies to facilitate the investigation of life science. Recently, DDA platform announces the release of its comprehensive GPCR assay which can be applied to accelerate life science research, solve complex analytical challenges, and increase laboratory productivity.
Creative Bioarray provides a comprehensive selection of combined and functional GPCR analysis to satisfy the needs of GPCR drug discovery research. The design and application of high-throughput GPCR analysis is critical for early drug discovery, which can cost-effectively screen large compound libraries to identify new drug candidates. Early functional GPCR analysis mainly relied on the measurement of G protein-mediated second messengers. With the ever-increasing understanding of GPCR signal transduction, many G protein-independent pathways can be used to detect the activity of GPCRs and provide other information for the functional selectivity of candidate compounds.
Combining automatic imaging system and labelless detection system, DDA platform is capable to provide diverse types of GPCR assays:
The receptor binding assays performed by Creative Bioarray are specifically designed to support analysis such as in vitro screening, pharmacokinetics (PK), immunogenicity and biomarker studies. They are used in all stages of the drug discovery process, from drug screening to post-marketing monitoring. And this assay is featured with high-throughput; less interference and agonist & antagonist in one assay.
The biggest advantage of the GTPγS binding assay is that it can measure the functional outcome of receptor occupancy during early receptor-mediated events, which means that it can be used to provide traditional pharmacological parameters of potency, efficacy and antagonist affinity. DDA platform has enabled this assay to identify receptor-coupled specific G proteins, study agonist-directed transport and use it in a high-throughput format.
Besides, DDA platform can support G-protein independent assays which include GPCR internalization assay, Label-free whole cell assay etc. and receptor dimerization assay including techniques based on traditional biochemistry, such as cyanogen polyacrylamide gel electrophoresis (BN-PAGE), co-immunoprecipitation and complementary analysis of protein fragments, and techniques based on resonance energy transfer, fluorescence resonance energy transfer (FRET), time-resolved FRET, FRET spectroscopy and bioluminescence resonance energy transfer (BRET), etc.
“Creative Bioarray can provide multiple assays formats to choose, and the assays offered are featured with customized GPCR stable cell line generation and high QC standards with attractive price, we have a team of professionals are dedicated to providing precise and reproducible results with rapid turnaround time,” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Creative Bioarray offers hundreds of functional and radioligand-binding GPCR assays which involves pre-defined GPCR panel and customized GPCR panel for high-throughput screening, molecular pharmacology and molecular profiling.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.